Rashmi G Mathew1, Beng T Goh2, Mark C Westcott2. 1. Moorfields Eye Hospital, London, United Kingdom. 2. Moorfields Eye Hospital, London, United Kingdom Royal London Hospital, Barts Health NHS Trust, London, United Kingdom.
Abstract
PURPOSE: The British Ocular Syphilis Study (BOSS) is the first national prospective epidemiological study of intraocular syphilis (IOS) in light of the global increase in early syphilis (ES). The aims were to ascertain the UK incidence, demographics, clinical features, laboratory data, and posttreatment visual outcomes of patients with IOS. METHODS: Prospective study of IOS, reported through the national reporting system (British Ocular Surveillance Unit) from 2009 to 2011. Case definition was any adult presenting with intraocular inflammation in ES. RESULTS: A total of 41 new cases (63 eyes) of IOS were reported, giving an annual incidence of 0.3 per million UK adult population. Mean age was 48.7 years (range, 20.6-75.1); 90.2% were male. All had RPR/VDRL titers of ≥1:16. Bilateral ocular involvement occurred in 56%; in unilateral cases, the left eye was more commonly affected (P = 0.009). Mean presenting logMAR visual acuity was 0.52 (20/63 Snellen; range, -0.2 to 2.30 logMAR). Panuveitis was the commonest diagnosis, seen in 41.3%, and isolated anterior uveitis was uncommon (9.5%). Subgroup analysis between HIV-positive and -negative patients found no significant differences in terms of proportion of bilateral disease, presenting or post treatment acuity. HIV-positive patients had higher rates of panuveitis. At final follow-up, 92.1% had visual acuity ≥ 0.3 logMAR (20/40 Snellen) after antibiotic therapy. CONCLUSIONS: This study is the largest prospective series of ocular syphilis in the post-penicillin era. It confirms good visual outcomes for treated IOS, irrespective of HIV status or time to presentation. The study identified an unexpected preponderance for left eye involvement in uniocular cases; which is unexplained. Copyright 2014 The Association for Research in Vision and Ophthalmology, Inc.
PURPOSE: The British Ocular Syphilis Study (BOSS) is the first national prospective epidemiological study of intraocular syphilis (IOS) in light of the global increase in early syphilis (ES). The aims were to ascertain the UK incidence, demographics, clinical features, laboratory data, and posttreatment visual outcomes of patients with IOS. METHODS: Prospective study of IOS, reported through the national reporting system (British Ocular Surveillance Unit) from 2009 to 2011. Case definition was any adult presenting with intraocular inflammation in ES. RESULTS: A total of 41 new cases (63 eyes) of IOS were reported, giving an annual incidence of 0.3 per million UK adult population. Mean age was 48.7 years (range, 20.6-75.1); 90.2% were male. All had RPR/VDRL titers of ≥1:16. Bilateral ocular involvement occurred in 56%; in unilateral cases, the left eye was more commonly affected (P = 0.009). Mean presenting logMAR visual acuity was 0.52 (20/63 Snellen; range, -0.2 to 2.30 logMAR). Panuveitis was the commonest diagnosis, seen in 41.3%, and isolated anterior uveitis was uncommon (9.5%). Subgroup analysis between HIV-positive and -negative patients found no significant differences in terms of proportion of bilateral disease, presenting or post treatment acuity. HIV-positive patients had higher rates of panuveitis. At final follow-up, 92.1% had visual acuity ≥ 0.3 logMAR (20/40 Snellen) after antibiotic therapy. CONCLUSIONS: This study is the largest prospective series of ocular syphilis in the post-penicillin era. It confirms good visual outcomes for treated IOS, irrespective of HIV status or time to presentation. The study identified an unexpected preponderance for left eye involvement in uniocular cases; which is unexplained. Copyright 2014 The Association for Research in Vision and Ophthalmology, Inc.
Authors: Sara Oliver; Sharon K Sahi; Lauren C Tantalo; Charmie Godornes; Robyn Neblett Fanfair; Lauri E Markowitz; Sheila A Lukehart; Christina M Marra Journal: Sex Transm Dis Date: 2016-08 Impact factor: 2.830
Authors: Elen A Romao; Valdes R Bolella; Maria Estela P Nardin; Maria Lucia Habib-Simao; João Marcelo Furtado; Miguel Moyses-Neto Journal: Rev Inst Med Trop Sao Paulo Date: 2016-05-24 Impact factor: 1.846
Authors: Anna B Cope; Victoria L Mobley; Sara E Oliver; Mara Larson; Nicole Dzialowy; Jason Maxwell; Jessica L Rinsky; Thomas A Peterman; Aaron Fleischauer; Erika Samoff Journal: Sex Transm Dis Date: 2019-02 Impact factor: 2.830
Authors: Sara E Oliver; Anna Barry Cope; Jessica L Rinsky; Charnetta Williams; Gui Liu; Stephanie Hawks; Thomas A Peterman; Lauri Markowitz; Aaron T Fleischauer; Erika Samoff Journal: Clin Infect Dis Date: 2017-10-30 Impact factor: 9.079
Authors: Katherine S Hu; Albert T Vitale; Akbar Shakoor; Marissa Larochelle; Therese Sassalos; Susan G Elner; Thiran Jayasundera; Christopher D Conrady Journal: Ophthalmol Retina Date: 2021-07-02